Lumea and Valar Labs today announced a partnership to integrate Valar Labs' Vesta tests into the Lumea digital pathology platform. LEHI, UT, UNITED STATES, October 9, 2025 /EINPresswire.com/ -- Lumea, the U.S. leader in primary clinical...

Paige and Janssen will collaborate to deploy an AI-powered, H&E-based biomarker test, developed by Janssen, to screen for actionable FGFR2 and FGFR3 genomic alterations within seconds Goal is to provide physicians with important insights...

Artificial intelligence: A promising frontier in bladder cancer diagnosis and outcome prediction Abstract Bladder cancer (BCa) is the most common malignancy of the urinary tract and the most expensive malignancy to treat over the...